Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular to Present a Corporate Overview at the H.C. Wainwright 20th Annual Global Investment Conference
TUCSON, Ariz. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the H.C.
Toggle Summary HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, a Comprehensive Panel for miRNA Expression Analysis for use in Translational Medicine and Preclinical Studies
TUCSON, Ariz. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay
Toggle Summary HTG Molecular Announces 2nd Amendment to Second Statement of Work with QIAGEN Manchester Limited
TUCSON, Ariz. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into a second amendment to the second statement of work (“SOW Two”)
Toggle Summary HTG Molecular Appoints Michelle R. Griffin to its Board of Directors
TUCSON, Ariz. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Ms. Michelle Griffin to its Board of Directors.  “We are pleased to
Toggle Summary HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel
TUCSON, Ariz. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first

Stock Chart

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event